Labelling Review row-Online

Primary Antibodies
Cytokeratin, Multi (5/6/8/18)
Clone 5D3, Clone LP34 cocktail
1 mL, 0.1 mL lyophilized NCL-CK5/6/8/18 F P (Enzyme)
1 mL liquid NCL-L-CK5/6/8/18 F P (Enzyme)
7 mL ready-to-use RTU-CK5/6/8/18 F P (Enzyme)
See also Multi-Cytokeratin (5/6/8/18) on page 137.
Cytomegalovirus Antibodies
Clone 2, Clone 6 cocktail
1 mL, 0.1 mL lyophilized Cytomegalovirus (pp65 antigen)
NCL-CMVpp65 P (HIER) W I
Clone QB1/42
1 mL lyophilized Cytomegalovirus (early antigen)
NCL-CMV-EA F P (HIER)
Clone QB1/06
1 mL lyophilized Cytomegalovirus (late antigen)
NCL-CMV-LA F P (HIER)
Cytomegalovirus (CMV) is an opportunistic pathogen infecting lung, kidney,
gut and other organs in situations where an individual is immunologically
immature, such as the fetus and neonate. Infection also occurs in immunosuppressed
individuals eg transplant recipients, individuals undergoing
chemotherapy and those with HIV infection. The typical course of an active
CMV infection in the immunosuppressed individual is reported to be
characterized by a period of pp65 antigenaemia which correlates with viral
replication. This may be observed over some weeks and begins before the
onset of clinical symptoms. Following the isolation of CMV strains in cell
culture, early viral proteins are expressed in the cell nucleus, within 3 to 24
hours of infection. After 48 to 72 hours, a number of late viral proteins may
be demonstrated in the nucleus and cytoplasm of infected cells.
Product Specific Information
NCL-CMVpp65 is a pool of 2 unique monoclonal antibodies suitable for the
detection of the pp65 antigen in cytospin preparations.
Antigenaemia positive peripheral polymorphonuclear leukocytes: immunofluorescence for
Cytomegalovirus pp65 antigen using NCL-CMVpp65. Note characteristic nuclear staining.
Formalin/sucrose-fixed cytospin preparation.
/ 100
For detailed information on all products please visit our website:
www.leica-microsystems.com
Daxx
Clone 36H11
1 mL lyophilized NCL-DAXX P (HIER)
Daxx binds the death domain of Fas and links this receptor to an apoptosis
pathway involving the activation of Jun N-terminal kinase (JNK). The human
homolog of Daxx enhances Fas-mediated apoptosis probably by modulating
the transcription of genes involved in Fas-induced caspase activation and
apoptosis. The Fas-binding domain of Daxx is a dominant negative inhibitor
of both Fas-induced apoptosis and JNK inactivation, while the FADD death
domain partially inhibits death but not JNK activation. The Daxx apoptotic
pathway is sensitive to both bcl-2 and dominant negative JNK pathway
components and acts cooperatively with the FADD pathway. Therefore,
Daxx and FADD define two distinct pathways downstream of Fas. Daxx
mRNA is widely expressed in human tissues such as heart, brain, lung, liver,
skeletal muscle, kidney, pancreas and placenta. The human Daxx gene has
been mapped to 6p21.3 in the major histocompatibility complex (MHC)
region. Its location may help in understanding the genetic basis of autoimmune
diseases. In cells, the protein is found in the nucleus and to a lesser
extent in the cytoplasm.
Human breast carcinoma: immunohistochemical staining for Daxx using NCL-DAXX. Note
cytoplasmic and occasional nuclear staining. Paraffin section.
DEC-205 (CD205)
Clone 11A10
1 mL liquid NCL-L-DEC205 P (HIER) P (HIER)
See also CD205 (DEC-205) on page 88.
Products in this catalog are subject to regulatory approval.
This catalog is not for use in the USA.